Ingredients

Lactobacillus Reuteri: Benefits, Dosage, Evidence & Side Effects (2026)

What Is Lactobacillus Reuteri? Lactobacillus reuteri (also written as Limosilactobacillus reuteri following recent taxonomic reclassification) is a species of lactic acid-producing bacteria that naturally inhabits the gastrointestinal tracts of humans and many…

What Is Lactobacillus Reuteri?

Lactobacillus reuteri (also written as Limosilactobacillus reuteri following recent taxonomic reclassification) is a species of lactic acid-producing bacteria that naturally inhabits the gastrointestinal tracts of humans and many other mammals and birds. It is considered a commensal organism, meaning it can coexist with its host in a mutually beneficial or neutral relationship under normal circumstances.

First isolated in the early twentieth century and later named after German microbiologist Gerhard Reuter, L. reuteri is found in human breast milk, the oral cavity, the stomach, the small intestine, and the colon. It is one of the few Lactobacillus species that colonizes multiple body sites. In supplement form, it is typically produced through controlled bacterial fermentation and delivered as freeze-dried powder in capsules, tablets, drops, or lozenges. Its presence in the gut tends to diminish with age, antibiotic use, and poor diet, which has contributed to scientific interest in supplementation.

How Lactobacillus Reuteri Works

L. reuteri exerts its effects through several proposed mechanisms, though not all are fully characterized in humans.

  • Production of reuterin: This bacterium produces a broad-spectrum antimicrobial compound called reuterin (3-hydroxypropionaldehyde), which may inhibit the growth of pathogenic bacteria, fungi, and some viruses in the gut without substantially disrupting other beneficial microorganisms.
  • Modulation of the immune system: Research suggests L. reuteri interacts with intestinal immune cells, potentially promoting regulatory T-cell activity and influencing cytokine production. This may contribute to anti-inflammatory effects, though the clinical relevance in humans is still being studied.
  • Gut barrier support: Some laboratory and animal studies indicate this organism may help maintain the integrity of the intestinal epithelial lining, potentially reducing permeability, though human evidence remains limited.
  • Influence on the gut-brain axis: Preclinical research has explored L. reuteri’s possible effects on the vagus nerve and neurotransmitter signaling, including oxytocin pathways. These findings come largely from animal models and have not been firmly established in controlled human trials.
  • Competitive exclusion: By colonizing mucosal surfaces and competing for adhesion sites and nutrients, L. reuteri may limit the ability of harmful bacteria to establish themselves in the digestive tract.

Evidence & Research

The overall evidence for L. reuteri is mixed to moderate, with some areas showing stronger support than others.

Infant colic: This is one of the better-supported applications. Several randomized controlled trials suggest that L. reuteri DSM 17938 may reduce crying time in breastfed infants with colic. A 2014 meta-analysis and subsequent studies have supported this finding, though results are less consistent in formula-fed infants.

Helicobacter pylori: Evidence is mixed but moderately encouraging. Some trials suggest that L. reuteri used alongside standard antibiotic therapy may modestly improve eradication rates and reduce antibiotic-associated side effects, though it is not a standalone treatment.

Digestive health and diarrhea: Limited to moderate evidence suggests potential benefits in reducing duration of certain types of diarrhea and managing general gastrointestinal discomfort, though study quality and strain specificity vary considerably.

Oral health: Preliminary studies indicate L. reuteri delivered via lozenges may help reduce gum inflammation and dental plaque, but research is early-stage.

Cholesterol, bone density, testosterone, and mood: These areas have generated interest based largely on animal studies or small, short-term human trials. Evidence is currently preliminary and insufficient to draw firm conclusions.

Typical Dosage

Dosages used in research and seen on supplement labels vary considerably depending on the intended use and the specific strain. Most clinical studies have used doses in the range of 100 million (1 × 10⁸) to 100 billion (1 × 10¹¹) colony-forming units (CFU) per day. For infant colic, studies have typically used approximately 100 million CFU daily. Adult studies addressing gut health or H. pylori often use higher doses.

Dosing frequency, strain identity (such as DSM 17938 or ATCC PTA 6475), and delivery format (drops, tablets, lozenges) all influence outcomes observed in research. There is no universally established optimal dose. Individuals considering supplementation should consult a qualified healthcare provider, as appropriate dosing depends on the specific health context.

Potential Benefits

Based on available research, L. reuteri supplementation may support:

  • Reduction in crying duration associated with infant colic in breastfed infants
  • Adjunct support during H. pylori eradication therapy, potentially improving tolerability
  • General gastrointestinal comfort, including reduced bloating and irregularity in some individuals
  • Oral mucosal health when delivered in lozenge form, based on limited evidence
  • Maintenance of a balanced gut microbial environment, particularly following antibiotic use

It is important to note that many proposed benefits remain under active investigation, and results are not guaranteed or uniform across populations.

Side Effects & Safety

L. reuteri is generally considered safe for healthy adults and infants when used at studied doses. It carries GRAS (Generally Recognized as Safe) status in the United States for certain applications. Reported side effects are typically mild and may include:

  • Temporary bloating or increased intestinal gas
  • Mild nausea or loose stools, particularly at the start of supplementation
  • Temporary changes in bowel habits

Serious adverse events are rare in healthy individuals. However, probiotics as a general category have been associated with bacteremia (bacteria entering the bloodstream) in severely immunocompromised individuals, though this is uncommon and not specific to this strain alone.

Who Should Avoid It

Certain populations should exercise caution or consult a healthcare professional before using L. reuteri supplements:

  • Immunocompromised individuals: People with HIV/AIDS, organ transplant recipients, those undergoing chemotherapy, or others with significantly weakened immune systems face a theoretically elevated risk of probiotic-related infections.
  • Critically ill patients: Use of probiotics in intensive care or surgical settings carries specific risks and should only occur under medical supervision.
  • Individuals with central venous catheters: There are case reports of probiotic bacteremia linked to catheter use; medical guidance is advised.
  • Pregnant and breastfeeding individuals: Limited specific safety data exists for this population. While generally considered low risk, consultation with a healthcare provider is recommended before use.
  • Those taking immunosuppressant medications: Potential interactions with the immune system warrant medical oversight.
  • Infants with serious underlying health conditions: While studied in healthy infants with colic, use in premature or medically fragile newborns requires medical supervision.

Scientific References

Peer-reviewed studies on Lactobacillus Reuteri are indexed on PubMed (National Library of Medicine).

Supplements Containing Lactobacillus Reuteri

You can find Lactobacillus Reuteri in these products we have reviewed:

🕸️ Explore Our Research Web

More Reviews